ISIS 681257 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Elevated Lipoprotein(a)
Conditions
Elevated Lipoprotein(a), Cardiovascular Disease
Trial Timeline
Mar 7, 2017 → Nov 13, 2018
NCT ID
NCT03070782About ISIS 681257 + Placebo
ISIS 681257 + Placebo is a phase 2 stage product being developed by Ionis Pharmaceuticals for Elevated Lipoprotein(a). The current trial status is completed. This product is registered under clinical trial identifier NCT03070782. Target conditions include Elevated Lipoprotein(a), Cardiovascular Disease.
What happened to similar drugs?
0 of 4 similar drugs in Elevated Lipoprotein(a) were approved
Approved (0) Terminated (2) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03070782 | Phase 2 | Completed |
Competing Products
12 competing products in Elevated Lipoprotein(a)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Muvalaplin + Placebo | Eli Lilly | Phase 3 | 47 |
| Baricitinib | Eli Lilly | Pre-clinical | 26 |
| Rosuvastatin | AstraZeneca | Phase 3 | 32 |
| TQJ230 + Placebo | Novartis | Phase 3 | 44 |
| LIK066 + Placebo | Novartis | Phase 2 | 35 |
| Olpasiran | Amgen | Phase 1 | 29 |
| Maridebart cafraglutide + Placebo | Amgen | Phase 2 | 42 |
| Ivabradine | Amgen | Phase 3 | 32 |
| ALN-PCS02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 26 |
| ISIS-APO(a)Rx + Placebo | Ionis Pharmaceuticals | Phase 2 | 32 |
| APOC-III-L-Rx + Placebo Comparator | Ionis Pharmaceuticals | Phase 1 | 26 |
| IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl) | Ionis Pharmaceuticals | Phase 1 | 26 |